PURENCT06886191
puO2 in RenalGuard Pilot Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
- Completed without a posted recruiting period
- Primary completion date changed from estimate of Dec 31, 2026 to Jun 12, 2026
- Study sites: 0 to 1
- Study completion date changed from estimate of Dec 31, 2026 to Jun 15, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
The RG system is used to ensure neutral (0) fluid balance while maintaining a urine flow \>200 ml/hour. Urine output is replaced 1:1 with Plasmolyte solution. In patients randomized to RG, therapy is initiated after baseline measurements but before the start of surgery. If baseline urine flow is \< 200 ml/hour, a bolus dose of furosemide (20 mg iv) is given, and additional furosemide bolus and/or titration of continuous furosemide infusion may be given to maintain urine flow rate \>200ml/hour. After completed surgery, RG therapy continues until 3 hours after weaning from CPB
Conduct of cardiopulmonary bypass will be done according to local clinical practice
Devices: RenalGuard Therapy
Sites
1 site in 1 country
- Department of Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University HospitalGothenburg, Sweden